$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Telisotuzumab-Optional treatment options and clinical research summary after EMRELIS resistance
2026-02-01 22:25:32
Check Details
Are tovorafenib and tovatinib the same and analysis of differences in pharmacological effects and indications
2026-02-01 22:25:32
Check Details
Effect and clinical research summary of vorasidenib-VORANIGO in the treatment of vulvovaginal candidiasis
2026-02-01 22:25:32
Check Details
Are zongertinib and zonertinib the same and analysis of differences in pharmacological effects and clinical applications
2026-02-01 22:25:32
Check Details
Analysis of how much height can be gained after vosoritide injection and data analysis on efficacy and height improvement of different patients
2026-02-01 22:25:32
Check Details
What diseases does Mecobalamin mainly treat and its common clinical indications?
2026-02-01 22:25:32
Check Details
Cobimetinib tablet specifications and dosage introduction and patients’ actual medication experience
2026-02-01 22:25:32
Check Details
KRAS mutated lung cancer is no longer untreatable - the latest clinical and drug purchasing guide for Sotorasib
2026-02-01 22:25:32
Check Details
The latest scientific research and marketing news on pemetinib/dabotan
2026-02-01 22:25:32
Check Details
Erdafitinib Bangladesh version drug introduction
2026-02-01 22:25:32
Check Details
What kind of drug does dacomitinib/dacomitinib (Dozerun) belong to and its main indications?
2026-02-01 22:25:32
Check Details
What are the adverse reactions of entrectinib/Luo Shengquan?
2026-02-01 22:25:32
Check Details
1
2
...
2292
2293
2294
2295
2296
2297
2298
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
2
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
3
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
4
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
5
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
6
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
7
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
8
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
9
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
10
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
11
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management
12
Lemborexant: A Dual Orexin Receptor Antagonist Revolutionizing Insomnia Treatment